Suppliers for CAS
503612-47-3
|
Properties | CAS |
503612-47-3 | Formula |
C25H25N5O4 |
|
|
18 Registered suppliers
Amadis Chemical Company Limited
P.R.China
More details are to be found here
H&Z Industry Co.,Ltd
P.R.China
More details are to be found here
Hangzhou Meite Industry Co., Ltd (Hangzhou Meite Chemical Co., Ltd)
P.R.China
More details are to be found here
Capot Chemical Co., Ltd.
P.R.China
More details are to be found here
Leap Chem Co., Ltd
P.R.China
Molecular Formula: C25H25N5O4 Molecular Weight: 459.504
More details are to be found here
Regent Science Industry Limited
P.R.China
Molecular Formula: C25H25N5O4 Molecular Weight: 459.504
More details are to be found here
Shanghai Haoyuan Chemexpress Co., Ltd.
P.R.China
Wuhan PharmChem Co., LTD.
P.R.China
EINECS :639-684-6 Molecular formula :C25H25N5O4
Aea.ltd
P.R.China
EINECS :639-684-6 Molecular formula :C25H25N5O4
Hangzhou Zhongqi Chem Co., Ltd
P.R.China
EINECS :639-684-6 Molecular formula :C25H25N5O4
Hangzhou Lingrui Chemical Co., Ltd.
P.R.China
EINECS :639-684-6 Molecular formula :C25H25N5O4
BOC Sciences
USA
Description : Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb. - Molecular Weight :459.506
- Boiling Point :770.5±60.0 °C at 760 mmHg
- Purity :0.98
Molecular Formula : C25H25N5O4 Canonical SMILES : COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N InChI : InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) InChIKey : QNZCBYKSOIHPEH-UHFFFAOYSA-N Solubility : 0.11mg/mL Appearance : White powder Application : Factor Xa Inhibitors Synonyms : BMS-562247-01; BMS 562247-01; BMS562247-01; brand name: Eliquis
More details are to be found here
Shandong SanYoung Industry Co., Ltd
P.R.China
Description : Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb. - Molecular Weight :459.506
- Boiling Point :770.5±60.0 °C at 760 mmHg
- Purity :0.98
Molecular Formula : C25H25N5O4 Canonical SMILES : COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N InChI : InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) InChIKey : QNZCBYKSOIHPEH-UHFFFAOYSA-N Solubility : 0.11mg/mL Appearance : White powder Application : Factor Xa Inhibitors Synonyms : BMS-562247-01; BMS 562247-01; BMS562247-01; brand name: Eliquis
More details are to be found here
AK Scientific, Inc.
USA
Description : Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb. - Molecular Weight :459.506
- Boiling Point :770.5±60.0 °C at 760 mmHg
- Purity :0.98
Molecular Formula : C25H25N5O4 Canonical SMILES : COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N InChI : InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) InChIKey : QNZCBYKSOIHPEH-UHFFFAOYSA-N Solubility : 0.11mg/mL Appearance : White powder Application : Factor Xa Inhibitors Synonyms : BMS-562247-01; BMS 562247-01; BMS562247-01; brand name: Eliquis
More details are to be found here
Chemos GmbH & Co. KG
Germany
Description : Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb. - Molecular Weight :459.506
- Boiling Point :770.5±60.0 °C at 760 mmHg
- Purity :0.98
Molecular Formula : C25H25N5O4 Canonical SMILES : COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N InChI : InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) InChIKey : QNZCBYKSOIHPEH-UHFFFAOYSA-N Solubility : 0.11mg/mL Appearance : White powder Application : Factor Xa Inhibitors Synonyms : BMS-562247-01; BMS 562247-01; BMS562247-01; brand name: Eliquis
More details are to be found here
BuGuCh & Partners
Germany
Description : Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb. - Molecular Weight :459.506
- Boiling Point :770.5±60.0 °C at 760 mmHg
- Purity :0.98
Molecular Formula : C25H25N5O4 Canonical SMILES : COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N InChI : InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) InChIKey : QNZCBYKSOIHPEH-UHFFFAOYSA-N Solubility : 0.11mg/mL Appearance : White powder Application : Factor Xa Inhibitors Synonyms : BMS-562247-01; BMS 562247-01; BMS562247-01; brand name: Eliquis
More details are to be found here
CM Fine Chemicals
Switzerland
Description : Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb. - Molecular Weight :459.506
- Boiling Point :770.5±60.0 °C at 760 mmHg
- Purity :0.98
Molecular Formula : C25H25N5O4 Canonical SMILES : COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N InChI : InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) InChIKey : QNZCBYKSOIHPEH-UHFFFAOYSA-N Solubility : 0.11mg/mL Appearance : White powder Application : Factor Xa Inhibitors Synonyms : BMS-562247-01; BMS 562247-01; BMS562247-01; brand name: Eliquis
More details are to be found here
Santa Cruz Biotechnology, Inc.
USA
Description : Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb. - Molecular Weight :459.506
- Boiling Point :770.5±60.0 °C at 760 mmHg
- Purity :0.98
Molecular Formula : C25H25N5O4 Canonical SMILES : COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N InChI : InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) InChIKey : QNZCBYKSOIHPEH-UHFFFAOYSA-N Solubility : 0.11mg/mL Appearance : White powder Application : Factor Xa Inhibitors Synonyms : BMS-562247-01; BMS 562247-01; BMS562247-01; brand name: Eliquis
More details are to be found here
Detailed information on the suppliers of
|